Small Cap Stocks To Watch Now – November 4th

Spring Valley Acquisition, MSP Recovery, Direxion Daily PLTR Bull 2X Shares, Papa John’s International, and Sarepta Therapeutics are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively small market capitalizations—commonly defined as roughly $300 million to $2 billion, though exact cutoffs vary by index provider. They often offer higher growth potential but come with greater volatility, lower liquidity, and higher risk compared with mid- and large-cap stocks. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Spring Valley Acquisition (SV)

MSP Recovery (LIFW)

MSP Recovery, Inc., doing business as LifeWallet, operates as a healthcare recovery and data analytics company in the United States and Puerto Rico. The company offers claims recovery services, including services to related parties or third parties to assist entities with pursuit of claims recovery rights.

Direxion Daily PLTR Bull 2X Shares (PLTU)

Papa John’s International (PZZA)

Papa John’s International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.